Skip navigation

Press Release Archive

BPGbio, Inc. acquired substantially all of the assets of Berg, LLC, and licenses from Berg, LLC the use of the Berg and Berg Health names.

Sign up here to receive news updates via email.

  • June 3, 2024 | Press Releases, Media, News and Updates

    BPGbio Appoints Biopharma Industry Leader Scott Minick to Board of Directors

    BPGbio, Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced that seasoned biotech leader and venture capital investor, Scott Minick, has been elected to its Board of Directors. Mr. Minick will advise the executive team in the company’s next phase of commercialization and partnering transactions using its NAi Interrogative Biology Platform.

    read more
  • May 20, 2024 | Media, News and Updates, Press Releases

    BPGbio Announces Publication in Scientific Reports on Validation of Novel Diagnostic Biomarker Panel for Parkinson’s Disease

    BPGbio, a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, announced today the publication of a significant, multi-year research effort titled “Identification and validation of N-acetylputrescine in combination with non-canonical clinical features as a Parkinson’s disease biomarker panel” in Scientific Reports.

    read more
  • May 7, 2024 | Media, News and Updates, Press Releases

    BPGbio Brings Late Clinical Stage Rare Disease and Oncology Assets to US and EU Pharma Partnering Summits

    BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced its participation in both the US Pharma Partnering Summit, scheduled for May 14-15, 2024, in San Diego and the EU Pharma Partnering Summit taking place May 22-23, 2024 in Basel, Switzerland. 

    read more
  • April 5, 2024 | Media, News and Updates, Press Releases

    BPGbio Presents Key Advances in its Oncology Pipeline related to the NAi Interrogative Biology Platform

    BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced the application of its NAi Interrogative Biology® Platform across several drug and diagnostic applications, following successful collaborations with Stanford University, University of Tennessee, Oak Ridge National Laboratory, and several leading hospitals across Mexico. The company will present four posters showcasing these research collaborations and provide updates on other internal research activities at the American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024, in San Diego, Calif.

    read more
  • February 21, 2024 | Media, News and Updates, Press Releases

    Lincoln Property Company, BPGbio, and Cresa Announce 70,000-sq.-ft. Lease at 300 Third Avenue in Waltham 

    Lincoln Property Company (“Lincoln”), Cresa Boston, and BPGbio, Inc, a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced that BPGbio has leased approx. 70,000 sq. ft. of lab and office space at 300 Third Avenue in Waltham, Mass. The company plans to relocate its headquarters from Framingham and expand into two full floors of the new space circa June 2025, significantly increasing its footprint in the Boston region.

    read more
  • January 21, 2024 | Media, News and Updates, Press Releases

    BPGbio Appoints Ritesh Srivastava as General Counsel

    BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced the appointment of Ritesh Srivastava as General Counsel. In this role, Mr. Srivastava will lead legal and compliance functions for the company as it grows its therapeutics and diagnostics businesses through R&D and new development and commercial partnerships. 

    read more